Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink by Murray, Liam J et al.
Post-diagnostic prescriptions for low-dose aspirin and breast
cancer-specific survival: a nested case-control study in a breast
cancer cohort from the UK Clinical Practice Research Datalink
Murray, L. J., Cooper, J. A., Hughes, C. M., Powe, D. G., & Cardwell, C. R. (2014). Post-diagnostic prescriptions
for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort




Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2014 Murray et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly credited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
RESEARCH ARTICLE Open Access
Post-diagnostic prescriptions for low-dose aspirin
and breast cancer-specific survival: a nested
case-control study in a breast cancer cohort
from the UK Clinical Practice Research Datalink
Liam J Murray1,2*, Janine A Cooper3, Carmel M Hughes3, Des G Powe4,5 and Chris R Cardwell1
Abstract
Introduction: Recent observational studies indicate that post-diagnostic use of aspirin in breast cancer patients
may protect against cancer progression perhaps by inhibiting cyclooxygenase-2 dependent mechanisms. Evidence
also supports a crucial role for interactions between tumour cells and circulating platelets in cancer growth and
dissemination, therefore, use of low-dose aspirin may reduce the risk of death from cancer in breast cancer patients.
Methods: A cohort of newly diagnosed breast cancer patients (1998 to 2006) were identified in the UK Clinical
Practice Research Datalink (and confirmed by cancer registry linkage). Cancer-specific deaths were identified up
to 2011 from Office for National Statistics mortality data. A nested case-control analysis was conducted using
conditional logistic regression to compare post-diagnostic aspirin exposure using General Practice prescription data
in 1,435 cases (breast cancer deaths) with 5,697 controls (matched by age and year of diagnosis).
Results: After breast cancer diagnosis, 18.3% of cancer-specific deaths and 18.5% of matched controls received at
least one prescription for low-dose aspirin, corresponding to an odds ratio (OR) of 0.98 (95% CI 0.83, 1.15). Adjustment
for potential confounders (including stage and grade) had little impact on this estimate. No dose response relationship
was observed when the number of tablets was investigated and no associations were seen when analyses were
stratified by receipt of prescriptions for aspirin in the pre-diagnostic period, by stage at diagnosis or by receipt of
prescriptions for hormone therapy.
Conclusions: Overall, in this large population-based cohort of breast cancer patients, there was little evidence of an
association between receipt of post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific death.
However, information was not available on medication compliance or over-the-counter use of aspirin, which may have
contributed to the null findings.
Introduction
Evidence is accumulating that aspirin may protect
against the development of some cancers, including
breast cancer; for example, meta-analyses of observa-
tional studies indicate that breast cancer risk is reduced
by 10 to 15% among aspirin users [1,2]. Recent evidence
also points to a possible protective effect of aspirin against
cancer progression in breast cancer patients. In the Iowa
Women’s Health Study, the risk of death from breast can-
cer in postmenopausal breast cancer patients was reduced
by approximately 50% among post-diagnostic users of
aspirin and non-aspirin non-steroidal anti-inflammatory
drugs (NSAIDs) [3]. Within the Nurses’ Health Study,
similar reductions in the risk of distant recurrence and
cancer-specific death were seen for breast cancer patients
using aspirin after diagnosis [4,5]. However, in the Life
After Cancer Epidemiology (LACE) study, post-diagnostic
use of aspirin was not associated with risk of breast cancer
recurrence, while users of ibuprofen had a substantial
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reduction in risk [6]. Each of these studies included pa-
tients with early stage disease (predominantly stage I and
II), were undertaken within the United States (US), aspirin
exposure was obtained by questionnaire and information
was not available on the dose of aspirin used. Use of
aspirin or non-aspirin NSAIDs at anti-inflammatory/
analgesic doses may affect cancer progression by inhi-
biting prostaglandin endoperoxide synthase-2 (PTSG-2,
cyclooxygenase-2) dependent mechanisms involved in
cancer cell proliferation, motility, invasion and angiogen-
esis [7,8]. However, a growing body of evidence also sup-
ports a crucial but complex role for interactions between
tumour cells and circulating platelets in cancer growth
and dissemination [9,10]. It is therefore possible that the
antiplatelet activity of (low-dose) aspirin may reduce the
risk of metastasis in cancer patients by, for example, pre-
venting angiogenesis or tumour cell extravasation and tis-
sue invasion [10,11].
We investigated the association between post-diagnostic
aspirin exposure and breast cancer-specific mortality in a
large cancer registry defined population-based cohort of
breast cancer patients in the United Kingdom (UK), in
whom aspirin exposure was determined from prescription
records. High dose aspirin is infrequently used in the UK
and the primary focus of this study was exposure to low
(antiplatelet) doses of aspirin.
Methods
Study design
A cohort study was conducted utilising recent linkages
between the English National Cancer Data Repository
(NCDR), the UK Clinical Practice Research Datalink
(CPRD) and the Office of National Statistics (ONS)
death registrations. The NCDR contains data on all can-
cer patients identified in English cancer registries, in-
cluding date and site of primary cancer diagnosis, stage
and treatment data. The CPRD is the world’s largest
database of longitudinal patient records comprising
around 6% of the UK population and includes demo-
graphic information, clinical diagnoses and prescription
data which are of documented high quality [12]. Ethical
approval for all observational research using CPRD data
has been obtained by the CPRD Group from a Multicen-
tre Research Ethics Committee (MREC). As the study
had no direct patient involvement, patient consent for
the study was not required. CPRD also contains ONS
mortality data providing date and cause of death for
deaths up to 2011.
Breast cancer patients were included if they had a
CPRD breast cancer diagnosis code and a NCDR diag-
nosis code of primary breast cancer (based upon a rele-
vant International Classification of Diseases (ICD) code
C50.0 to C50.9 (version 10) or 174.0 to 174.9 (version
9)) from 1998 to 2007. Breast cancer patients with a pre-
vious NCDR cancer diagnosis, apart from in situ neo-
plasms and non-melanoma skin cancers, were excluded.
The breast cancer cohort was linked to the CPRD (and
ONS) data using a deterministic algorithm based upon
the patient’s NHS number, gender, date of birth and
postcode. After linkage, patients were excluded if they
were prescribed hormone therapy (including tamoxifen
and aromatase inhibitors) from general practice (GP) re-
cords more than eight weeks prior to their cancer diag-
nosis, indicating an incorrect breast cancer diagnosis
date.
Exposure data
Aspirin prescriptions (from GP data) were classified as
low-dose if the drug strength was 75 mg or less (1.1% of
prescriptions after cancer diagnosis were 25 mg, 97.1%
75 mg, and 1.8% 300 mg or higher). Duration of use was
determined from the quantity of tablets prescribed. A
quantity of 28 tablets, based upon the average, was as-
sumed for less than 1% of prescriptions where quantity
was missing or assumed incorrect.
Covariates
Data available from NCDR included cancer stage, and
chemotherapy and radiotherapy in the six months after
diagnosis. Smoking, alcohol and body mass index (BMI)
were determined from the closest GP record prior to
breast cancer diagnosis (values older than 10 years were
ignored). GP prescribing data were used to determine
hormone therapy after cancer diagnosis (British National
Formulary (BNF) chapter 8.3.4.1, including tamoxifen
and aromatase inhibitors) and hormone replacement
therapy (HRT) for oestrogen and progestogens (BNF
chapters 6.4.1. and 6.4.2.) prior to diagnosis. GP pre-
scribing data were also used to determine other medica-
tion exposure (statins, angiotensin converting enzyme
(ACE) inhibitors, angiotensin receptor blockers (ARBs),
beta-blockers and metformin). Comorbidities, prior to
and during the relevant exposure period, were deter-
mined from GP diagnosis codes using a recent adapta-
tion of the Charlson comorbidity index [13].
Data analysis
The breast cancer cohort was initially analysed using a
nested case-control approach, a common approach
[14,15] which accounts for immortal time bias [16] with-
out requiring complicated statistical techniques [17] and
with minimal loss of precision [18]. Time varying covari-
ate cohort analyses were also applied and presented as
described later. Cases were members who had died due
to breast cancer (on the basis of an ICD code for breast
cancer as the underlying cause of death) and these were
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matched on age (in five year intervals) and year of cancer
diagnosis (in one year intervals) to four controls who were
alive after diagnosis for at least as long as their matched
case. The exposure period in cases was the period from
breast cancer diagnosis until six months prior to cancer-
specific death. The exposure period in the controls was of
the same duration as their matched cases starting from
the date of breast cancer diagnosis. Prescriptions in the six-
month period prior to death were removed as these may
reflect end of life treatment or increased exposure to
healthcare professionals (sensitivity analyses were also con-
ducted excluding prescriptions in one year and two years
prior to death). Consequently, the main analysis was re-
stricted to individuals with at least one year of follow-up.
Conditional logistic regression was used to compare the
risk of breast cancer-specific death by aspirin exposure
(defined by number of tablets or prescriptions) calculating
odds ratios (ORs) and 95% confidence intervals (95% CIs).
Adjusted analyses were conducted including potential
confounders, including stage, chemotherapy, radiotherapy,
exposure to tamoxifen or aromatase inhibitors, comorbidi-
ties (including myocardial infarction, cerebrovascular dis-
ease, congestive heart disease, chronic pulmonary disease,
peripheral vascular disease, peptic ulcer disease and dia-
betes) and pre-diagnosis smoking status. Similar analyses
were conducted for all-cause mortality (where up to three
controls were matched to each case). Various additional
sensitivity analyses were conducted. Analyses were con-
ducted excluding prescriptions in the first 12 months after
cancer diagnosis as these may be influenced by cancer
treatment. Analyses were conducted stratifying by aspirin
exposure in the year prior to diagnosis and a separate ana-
lysis was conducted investigating aspirin prescriptions in
the year prior to diagnosis. Analyses were also conducted
by stage and adjusting for stage when restricted to regis-
tries with higher rates of available stage information. An
analysis was also conducted in patients receiving prescrip-
tions for hormone therapy (a proxy for oestrogen receptor
positivity). All stratified analyses were conducted after re-
matching cases to controls within the strata of interest. In
another analysis, breast cancer-specific death was based
upon a breast cancer ICD code recorded as any cause of
death in ONS data, rather than just the underlying cause
of death as used in the main analysis. Sensitivity analyses
were also conducted analysing the entire breast cancer co-
hort, prior to conversion to case-control data, and apply-
ing survival analysis to investigate aspirin as a time
varying covariate [16] (in which an individual was a non-
user until first use and then remained a user until the end
of follow-up, applying a six-month lag to mimic the case-
control analysis). A separate analysis was conducted using
this time varying covariate approach and also accounting
for competing risk of deaths from other causes using the
proportional subhazards model [19].
The final analysis contained 1,435 breast cancer-
specific deaths and 5,697 matched controls, with low-
dose aspirin usage of approximately 20%. This allowed
80% power to detect as significant at the 5% level an
odds ratio of 0.80 in patients receiving low-dose aspirin
equivalent to a 20% risk reduction in breast cancer-
specific death. Statistical analyses were conducted in
STATA 11 (StataCorp, College Station, TX, USA).
Results
Patient cohort
Overall, there were 11,863 primary breast cancers diag-
nosed between 1998 and 2007 identified in NCDR, with
no previous record of cancer, that were linked to CPRD.
Of these, we excluded 894 because the diagnosis date
preceded CPRD research quality records, 116 due to un-
availability of death registration data, 879 because they
had less than one year of follow-up post diagnosis and
157 because hormone therapy records preceded the
breast cancer diagnosis date by more than eight weeks.
The final cohort for analysis therefore contained 9,817
breast cancer patients, with an average of 6.9 years of
follow-up (range 1.0 years to 13.0 years) in those not
dying, in whom there were 1,443 cancer-specific deaths.
The breast cancer cohort was converted to nested case-
control data with 1,435 cancer-specific deaths and 5,697
controls. No matched controls were available for eight
cases and an additional eight cases had only three
matched controls, seven had two matched controls and
seven had one matched control.
Patient characteristics
Table 1 shows characteristics of breast cancer-specific
deaths (cases) and controls. The average time to death in
the cases was 3.9 years and varied from 1 to 12.8 years.
There was a greater proportion of higher stage cancers
(P <0.001) and higher grade (P <0.001) in cases com-
pared with controls and cases were more likely to have
chemotherapy and less likely to have surgery within six
months of diagnosis, compared with controls. Current
smoking was more common in breast cancer-specific
deaths compared with controls (21.0% versus 18.4%).
Rates of comorbidities, alcohol consumption and BMI
levels prior to diagnosis were generally fairly similar be-
tween cases and controls (Table 1).
Association between receipt of prescriptions for aspirin
and survival
The association between receipt of prescriptions for as-
pirin and cancer-specific death is shown in Table 2.
There was little evidence of an association between re-
ceiving at least one prescription for low-dose aspirin
after cancer diagnosis and breast cancer-specific death
(adjusted OR = 1.00, 95% CI 0.71, 1.41; P = 0.99). There
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was also little evidence of dose response association be-
tween low-dose aspirin and breast cancer-specific death
when the number of prescriptions, tablets or prescriptions
per day was investigated. Finally, there was no significant
association between receiving at least one prescription for
high dose aspirin (prescribed for approximately 1% of
cases and controls) and cancer-specific mortality. Similar
analysis for all-cause mortality (see Table 3) showed little
evidence of associations between low-dose aspirin and
mortality.
Sensitivity analyses
Sensitivity analyses for the association between low-dose
aspirin exposure and cancer-specific death are shown in
Table 4. Findings were little altered when the exposure
period was varied or when aspirin prescriptions prior to
breast cancer diagnosis were investigated. There was also
no evidence of a difference in the association between
low-dose aspirin exposure after cancer diagnosis and
breast cancer-specific death when stratifying by aspirin
exposure prior to diagnosis, or when stratifying by stage
or when restricted to patients receiving hormone ther-
apy (within six months of diagnosis). No association was
seen in breast cancer patients diagnosed with early stage
disease (stage 1 and 2). Defining breast cancer-specific
death based upon a breast cancer code for any cause of
death, not necessarily the main cause, also had little im-
pact on the results (OR = 1.05, 95% CI 0.91, 1.20).
Restricting the adjusted analysis to cancer registries
where stage recording was 85% complete also had little
impact on the results. Repeating the analysis in the en-
tire breast cancer cohort using a Cox proportional haz-
ards model with a time varying covariate produced
similar estimates (hazard ratio (HR) = 1.06, 95% CI 0.92,
1.22) and additionally accounting for competing risks of
Table 1 Characteristics of breast cancer patients who






(n = 1,435) (n = 5,697)
Year of cancer diagnosis
1998 to 2000 500 (34.8%) 1,979 (34.7%) Matched
2001 to 2003 518 (36.1%) 2,060 (36.2%)
2003 to 2006 417 (29.1%) 1,658 (29.1%)
Age at cancer diagnosis
<40 92 (6.4%) 352 (6.2%) Matched
40 to 49 247 (17.2%) 985 (17.3%)
50 to 59 286 (19.9%) 1,144 (20.1%)
60 to 69 273 (19.0%) 1,092 (19.2%)
70 to 79 318 (22.2%) 1,271 (22.3%)
80 to 89 181 (12.6%) 722 (12.7%)
≥90 38 (2.7%) 131 (2.3%) Matched
Follow-up time (years):
mean (sd)
3.9 (2.3) 3.9 (2.3)
range 1.0 to 12.8 1.0 to 12.8
Grade
Well 54 (5.9) 751 (19.4) <0.001
Poor 377 (40.9) 1,900 (49.1)
Moderate 492 (53.3) 1,217 (31.5)
Missing 512 1,829
Stage
1 72 (11.0%) 1,133 (41.8%) <0.001
2 402 (61.5%) 1,379 (50.8%)
3 116 (17.7%) 167 (6.2%)





Surgery 1,087 (75.8%) 4,842 (85.0%) <0.001
Chemotherapy 573 (39.9%) 1,344 (23.6%) <0.001
Radiotherapy 2,703 (47.5%) 700 (48.8%) 0.31
Smoking prior to cancer
diagnosis
Non-smoker 710 (59.9%) 3,037 (64.0%) 0.03
Ex-smoker 226 (19.1%) 832 (17.5%)
Current smoker 249 (21.0%) 874 (18.4%)
Missing 250 954
Alcohol prior to cancer
diagnosis
Never consumed alcohol 203 (19.6) 806 (19.2) 0.94
Alcohol consumer 831 (80.4) 3,399 (80.8)
Missing 401 1,492
Table 1 Characteristics of breast cancer patients who
died from breast cancer (cases) compared with controls
(Continued)
BMI (kg/m2) prior to cancer
diagnosis:
1,049 4,333
Mean (SD) 26.6 (5.4) 26.3 (5.1) 0.04
Comorbidity prior to cancer
diagnosis
Cerebrovascular disease 67 (4.7) 219 (3.8) 0.15
Chronic pulmonary disease 249 (17.4) 906 (15.9) 0.18
Congestive heart disease 38 (2.7) 140 (2.5) 0.72
Diabetes 81 (5.6) 274 (4.8) 0.18
Myocardial infarction 20 (1.4) 79 (1.4) 0.97
Peptic ulcer disease 35 (2.4) 145 (2.6) 0.81
Peripheral vascular disease 35 (2.4) 73 (1.3) 0.001
Rheumatological disease 62 (4.3) 187 (3.3) 0.07
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deaths from other causes had little impact (sub-distribu-
tion HR = 1.04, 95% CI 0.81, 1.08).
Discussion
In this large UK population-based cohort of breast cancer
patients, there was little evidence of an association between
post-diagnostic exposure to low-dose aspirin (determined
from prescription records) and breast cancer-specific sur-
vival. This lack of association was seen irrespective of
whether the breast cancer patient had received prescriptions
for aspirin pre-diagnostically, and pre-diagnostic exposure
to low-dose aspirin was not associated with cancer-specific
mortality. No association was seen in breast cancer patients
diagnosed with early stage disease or in patients who re-
ceived prescriptions for hormone therapy (presumed to be
oestrogen receptor positive cases).
Data from two US studies, the Nurses’ Health Study [4]
and the Iowa Women’s Health Study [3], indicate a sub-
stantial (approximately 50%) reduction in risk of cancer
progression in early stage breast cancer patients using as-
pirin post-diagnostically, although another US study (the
LACE study) [6] did not observe any risk reduction in as-
pirin users and a study of breast cancer patients recruited
in New York state showed no association between recent
pre-diagnostic aspirin exposure and breast cancer survival
[20]. Information on aspirin dosage was not available in
these studies but high dose aspirin is more commonly
used in the US than in the UK [21]. Indications for aspirin
use were explored in the Nurses’ Health Study; 35% of
users took aspirin (most likely low-dose) for protection
against cardiovascular disease while 37% used aspirin (pre-
sumably high dose) for musculoskeletal pain, headache or
menstrual pain (data on other indications were not pro-
vided). Therefore, the reduction in risk of cancer progres-
sion seen in the US breast cancer studies may stem from
PTSG-2 inhibition by high dose aspirin rather than plate-
let inhibition from use of low-dose aspirin. Similar reduc-
tions in risk observed for non-aspirin NSAIDs [3,6], such
as ibuprofen, suggest that this is the case. Use of aspirin at
sufficient doses to cause PTSG-2 inhibition may be re-
quired to prevent breast cancer progression and although
platelets appear to play an important role in cancer pro-
gression [10], especially metastasis formation, our data do
not suggest a role for platelet inhibition by aspirin in the
prevention of breast cancer progression, even in patients
diagnosed with early stage disease.
This study has several strengths. It included a popula-
tion representative sample of breast cancer patients and
is the largest study in the field to date. Prior to this












for stage and grade
OR (95% CI)
P
No. prescriptions low dose
0 1,173 (81.7) 4,641 (81.5) 1.00 1.00 1.00
1 or more 262 (18.3) 1,056 (18.5) 0.98 (0.83, 1.15) 0.77 0.98 (0.81, 1.20) 0.86 1.00 (0.71, 1.41) 0.99
No. prescriptions low dose
0 1,173 (81.7) 4,641 (81.5) 1.00 1.00 1.00
1 to 11 117 (8.2) 525 (9.2) 0.88 (0.71, 1.09) 0.25 0.90 (0.71, 1.16) 0.42 0.80 (0.52, 1.24) 0.32
12 or more 145 (10.1) 531 (9.3) 1.08 (0.87, 1.33) 0.48 1.08 (0.84, 1.39) 0.57 1.28 (0.82, 2.01) 0.27
No. tablets low dose
0 1,173 (81.7) 4,641 (81.5) 1.00 1.00 1.00
1 to 365 90 (6.3) 385 (6.8) 0.93 (0.72, 1.19) 0.55 1.01 (0.77, 1.33) 0.93 0.93 (0.57, 1.52) 0.78
366 or more 172 (12.0) 671 (11.8) 1.01 (0.83, 1.22) 0.95 0.96 (0.76, 1.22) 0.76 1.05 (0.69, 1.58) 0.83
No. tablets low dose per day
0 1,173 4,641 (81.5) 1.00 1.00 1.00
0 to 0.5 93 (6.5) 370 (6.5) 0.99 (0.78, 1.27) 0.97 1.02 (0.78, 1.34) 0.89 0.89 (0.56, 1.42) 0.63
>0.5 169 (11.8) 686 (12.0) 0.97 (0.80, 1.17) 0.72 0.96 (0.76, 1.21) 0.73 1.10 (0.72, 1.67) 0.67
No prescriptions high dose
0 1,415 (98.6) 5,642 (99.0) 1.00 1.00 1.00
1 or more 20 (1.4) 55 (1.0) 1.47 (0.87, 2.46) 0.15 1.15 (0.65, 2.04) 0.62 1.11 (0.31, 4.04) 0.87
aModel includes chemotherapy within six months of diagnosis, radiotherapy within six months, tamoxifen (post diagnosis, during exposure period), aromatase
inhibitors (post diagnosis, during exposure period), comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease,
congestive heart disease, chronic pulmonary disease, peripheral vascular disease, peptic ulcer disease and diabetes), other medication exposure (post diagnosis, during
exposure period, including statins, beta-blockers, ACE inhibitors, ARBs and metfomin) and smoking (pre-diagnosis, with missing included as a category).
bAdjusted model additionally includes stage and grade, restricted to 574 cases and 2,268 controls with available data.
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work, the largest relevant study included 4,461 breast
cancer patients, in whom there were 292 breast cancer
deaths [4], whereas this study included 9,817 breast can-
cer patients and 1,443 cancer-specific deaths. We also
investigated receipt of aspirin prescriptions in the most
relevant exposure period; that is, following diagnosis
when treatments may be implemented to prevent cancer
progression. Thus far, only two other studies have inves-
tigated post-diagnostic exposure to aspirin [4,6]. Follow-
up in our study was for a reasonably long period in
order for sufficient events to occur and post-diagnostic
exposure to low-dose aspirin was common, allowing ad-
equate precision around the risk estimates. In contrast,
high dose aspirin was infrequently prescribed in our co-
hort and consequently risk estimates were imprecisely
estimated. The linkage with NCDR and ONS allowed ro-
bust verification of cancer diagnosis and death data. The
use of GP prescribed drug information eliminated the
potential for recall bias incurred by self-report, and
allowed temporal associations to be explored [22]. The
drug data reflect GP prescriptions, not drugs dispensed
or actually consumed, and compliance cannot be as-
sumed. The potential non-compliance of cases and
controls with prescribed aspirin therapy is a limitation of
this study, and may have contributed to the null find-
ings. However, we observed null associations in analyses
of patients who received multiple aspirin prescriptions
or those with at least one year’s prescription and so do
not believe that non-compliance greatly impacted upon
the results shown. Over-the-counter usage of aspirin in
cases and controls must be considered as our inability to
capture such use may have also contributed to the null
findings. However, the amount of over-the-counter use
is likely to be low as a previous General Practice Re-
search Database (GPRD) study [23] comparing prescrip-
tion records to patient self–report noted that the
majority of chronic aspirin therapy was captured by pre-
scription records and another estimated that 70% to 80%
of aspirin use in the age-group we investigated was pre-
scription based [24]. Furthermore, previous methodo-
logical studies have shown that even with high levels of
over the counter usage (much higher than is likely to
have occurred in our study) valid treatment effects can
be obtained using prescription databases [25].
We were unable to stratify analysis by tumour molecu-
lar subtypes or by tumour markers related to metastasis













for stage and grade
OR (95% CI)
P
No. prescriptions low dose
0 1,653 (73.2) 5,153 (76.5) 1.00 1.00 1.00
1 or more 605 (26.8) 1,580 (23.5) 1.23 (1.09, 1.38) 0.001 1.14 (0.99, 1.31) 0.07 1.19 (0.93, 1.52) 0.17
No. prescriptions low dose
0 1,653 (73.2) 5,153 (76.5) 1.00 1.00 1.00
1 to 11 246 (10.9) 704 (10.5) 1.11 (0.95, 1.31) 0.19 1.04 (0.87, 1.25) 0.64 1.13 (0.83, 1.56) 0.42
12 or more 359 (15.9) 876 (13.0) 1.33 (1.15, 1.54) <0.001 1.24 (1.04, 1.47) 0.02 1.23 (0.92, 1.66) 0.17
No. tablets low dose
0 1,653 (73.2) 5,153 (76.5) 1.00 1.00 1.00
1 to 365 192 (8.5) 487 (7.2) 1.25 (1.05, 1.50) 0.01 1.21 (0.99, 1.47) 0.06 1.18 (0.84, 1.67) 0.33
366 or more 413 (18.3) 1,093 (16.2) 1.21 (1.06, 1.39) 0.006 1.10 (0.94, 1.30) 0.23 1.19 (0.90, 1.59) 0.22
No. tablets (low dose) per day
0 1,653 (73.2) 5,153 (76.5) 1.00 1.00 1.00
0 to 0.5 225 (10.0) 590 (8.8) 1.21 (1.02, 1.44) 0.03 1.15 (0.95, 1.38) 0.16 1.22 (0.88, 1.67) 0.23
>0.5 380 (16.8) 990 (14.7) 1.24 (1.07, 1.42) 0.003 1.14 (0.97, 1.34) 0.12 1.17 (0.87, 1.57) 0.30
No prescriptions high dose
0 2,222 (98.4) 6,660 (98.9) 1.00 1.00 1.00
1 or more 36 (1.6) 69 (1.0) 1.48 (0.99, 2.21) 0.05 1.24 (0.81, 1.89) 0.32 0.94 (0.48, 1.84) 0.86
aModel includes chemotherapy within six months of diagnosis, radiotherapy within six months, tamoxifen (post diagnosis, during exposure period), aromatase
inhibitors (post diagnosis, during exposure period), comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease,
congestive heart disease, chronic pulmonary disease, peripheral vascular disease, peptic ulcer disease and diabetes), other medication exposure (post diagnosis, during
exposure period, including statins, beta-blockers, ACE inhibitors, ARBs and metfomin), and smoking (pre-diagnosis, with missing included as a category).
bAdjusted model additionally includes stage and grade, restricted to 888 cases and 2,628 controls with available data.
CI, Confidence interval; OR, Odds ratio.
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risk [26]. No association was observed in patients receiv-
ing prescriptions for hormone therapy (a proxy for
oestrogen receptor positivity) and previous investigators
have not seen differences in the association between as-
pirin exposure and breast cancer progression by hor-
mone receptor status [4,6]. However, further studies
should examine the association between aspirin use and
breast cancer progression according to relevant tumour
molecular characteristics. A further limitation was our
inability to study breast cancer metastasis or recurrence
as an outcome, since this information is not routinely
collected in the NCDR. Although it is possible that some
deaths have been incorrectly misclassified when deter-
mining cancer-specific mortality, simulations from a re-
cent methodological study indicate that in comparative
studies in which differential misclassification between
groups is unlikely, like ours, such misclassification is un-
likely to impact on effect estimates [27]. We did not
have complete data on potentially important con-
founders such as BMI and smoking and there also re-
mains the possibility of residual confounding from
unidentified confounders; however, previous reports did
not show evidence of substantial confounding of the as-
sociation between aspirin and breast cancer progression
by factors, such BMI, physical activity, smoking, race
and so on [3,4,6]. Although stage data were incomplete,
it seems unlikely that stage confounded the main finding
as adjustments for stage in the subset of cancer registries
where stage data were 85% complete had little influence
on risk estimates. Confounding by indication is often








P OR (95% CI) 1 to
11 low dose aspirin
prescriptions
vs. none
P OR (95% CI) 12




Main analysis: Diagnosis to six months
prior to death
1,435 5,697 0.98 (0.83, 1.15) 0.77 0.88 (0.71, 1.09) 0.25 1.08 (0.87, 1.33) 0.48
Post diagnostic aspirin in patients with
no pre-diagnostic aspirin prescriptionsb
1,125 4,457 0.82 (0.64, 1.04) 0.10 0.81 (0.59, 1.10) 0.17 0.84 (0.59, 1.18) 0.31
Post diagnostic aspirin in patients with
pre-diagnostic aspirin prescriptionsb
142 515 0.95 (0.52, 1.71) 0.86 0.82 (0.43, 1.56) 0.55 1.08 (0.57, 2.03) 0.81
Pre-diagnostic low dose aspirin
prescriptionsc
1,559 6,186 0.99 (0.83, 1.18) 0.93 1.01 (0.83, 1.22) 0.93 0.94 (0.67, 1.32) 0.71
Diagnosis to one year prior to deathd 1,272 5,048 1.06 (0.89, 1.26) 0.51 1.01 (0.80, 1.27) 0.95 1.11 (0.89, 1.40) 0.36
Diagnosis to two years prior to deathe 959 3,797 0.89 (0.72, 1.10) 0.28 0.62 (0.46, 0.85) 0.003 1.22 (0.93, 1.60) 0.15
One year after diagnosis to six months
prior to deathf
1,099 4,356 0.93 (0.77, 1.12) 0.43 0.84 (0.65, 1.09) 0.20 1.01 (0.79, 1.29) 0.94
Stage 1 and 2 breast cancer patients only 469 1,856 1.09 (0.82, 1.46) 0.54 0.83 (0.55, 1.24) 0.36 1.41 (0.98, 2.04) 0.07
Stage 3 and 4 breast cancer patients only 161 478 1.13 (0.68, 1.86) 0.64 1.24 (0.66, 2.33) 0.50 0.98 (0.45, 2.12) 0.96
Restricted to patients receiving prescriptions
for hormone therapy (in first six months)
875 3,466 1.08 (0.90, 1.30) 0.43 0.93 (0.72, 1.20) 0.55 1.23 (0.97, 1.56) 0.08
Patients with a recorded stage from cancer
registries with high rates of stage recording
(adjusted for stage)g
487 1,911 0.92 (0.67, 1.27) 0.62 0.95 (0.62, 1.45) 0.81 0.90 (0.59, 1.37) 0.62
Including breast cancer-specific deaths
where breast cancer is recorded as any
cause of death
1,786 7,090 1.05 (0.91, 1.20) 0.53 1.01 (0.84, 1.21) 0.95 1.09 (0.91, 1.30) 0.37
Time varying covariate analysish 1,440 8,374 1.06 (0.92, 1.22) 0.45 0.98 (0.81, 1.20) 0.88 1.13 (0.94, 1.35) 0.20
Time varying covariate analysisi 1,440 8,374 1.04 (0.90, 1.20) 0.60 0.96 (0.79, 1.67) 0.67 1.12 (0.93, 1.35) 0.22
aAll sensitivity analyses refer to low dose aspirin prescriptions in the time period from breast cancer diagnosis to six months before death, and are adjusted for
matching criteria only, unless otherwise stated.
bPre-diagnostic low dose aspirin prescriptions in one year prior to breast cancer diagnosis, restricted to individuals with one year of medication records prior
to diagnosis.
cPre-diagnostic low dose aspirin prescriptions in one year prior to breast cancer diagnosis.
dRestricted to individuals with at least 1.5 years of follow-up so relevant exposure period is at least a duration of six months.
eRestricted to individuals with at least 2.5 years of follow-up so relevant exposure period is at least a duration of six months.
fRestricted to individuals with at least two years of follow-up so relevant exposure period is at least a duration of six months.
gStage missing for 15% of individuals and breast cancer patients included from the Northern and Yorkshire Cancer Registry and Information Service, the Trent
Cancer Registry, the Eastern Cancer Registration and Information Centre, the Oxford Cancer Intelligence Unit and the West Midlands Cancer Intelligence.
hReported estimates are hazard ratios and 95% confidence intervals (CIs), adjusted for age and year of breast cancer diagnosis.
iReported estimates are sub-distribution hazards ratios and 95% CIs, adjusted for competing risks of death, age and year of breast cancer diagnosis.
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problematic within pharmaco-epidemiological studies
[28] and this may be expected in an examination of the
association between use of high dose aspirin or non-
aspirin NSAIDs and cancer progression as cancer patients
may use these drugs for pain relief; however, indication for
use is unlikely to confound the association between expos-
ure to low-dose aspirin and cancer progression as aspirin
at these doses is not used for the management of pain.
Regular use of aspirin has increased substantially in re-
cent years, for example, the proportion of the US popu-
lation taking aspirin at least three times a week over a
three-month period increased from 19.3% to 27.4% (1.4-
fold increase) between 2005 and 2010 [29]. Even higher
increases in use were seen for cancer patients, including
breast cancer patients in whom regular use increased
from 21.3% to 37.9% (1.8-fold increase). Reasons for pre-
scribing aspirin in the cancer patients was not available
nor was timing of prescribing with respect to the date of
cancer diagnosis so it is unclear whether aspirin was pre-
scribed in an attempt to prevent cancer progression.
Current evidence does not support aspirin use for such
an indication, but this is an active area of research. At
least one trial of aspirin therapy, including low-dose
therapy, in cancer patients, the Add-Aspirin Trial (in-
cludes breast cancer patients) is underway but it will not
report until 2020 at the earliest [30]. In the interim, data
from robust observational studies are informative.
Conclusion
In our study, there was little evidence of an association
between receipt of post-diagnostic prescriptions for low-
dose aspirin and breast cancer-specific death. However,
information was not available on medication compliance
or over-the-counter use of aspirin, which may have con-
tributed to the null findings.
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